ECTRIMS 2022 | Future studies on aHSCT for multiple sclerosis

Riccardo Saccardi, MD, Careggi University Hospital, Florence, Italy, discusses ongoing and future studies to improve the use of autologous hematopoietic stem cell transplantation (aHSCT) for the treatment of multiple sclerosis (MS). A clinical trial comparing aHSCT versus the best available therapy is ongoing, and its results are highly awaited. Studies investigating the long-term survival after aHSCT will provide important data about the potential of aHSCT to avoid the switch to the progressive phase of the disease. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.